Maria’s father used to be calm and kind. Now, he paces at night, snaps at loved ones, and says he’s being followed. He has dementia — but it’s not the memory loss that’s hardest. It’s the fear, the anger, the sadness that come out of nowhere.
Millions of families know this pain. Over 80% of people with dementia face behavioral and psychological symptoms — like anxiety, depression, aggression, or hallucinations. These aren’t just side effects. They can be more distressing than memory problems. And right now, doctors have few tools to treat them safely.
Most current drugs were made for other conditions, like schizophrenia or depression. They often don’t work well and can cause serious side effects, like falls or confusion. Doctors are stuck managing symptoms without knowing what’s really going on in the brain.
But here’s the twist: scientists may have finally found the hidden switches behind these emotional storms.
For the first time, researchers have mapped brain proteins in people who had dementia — and also tracked their mood and behavior while they were alive. They looked at 376 donated brains, focusing on a key area involved in thinking and emotion. Each person had detailed records of their symptoms, covering nine different types of mood and behavior changes.
The real breakthrough? Connecting specific proteins to specific symptoms.
Think of the brain like a busy city. Proteins are the workers — some run power plants, others fix roads, and some direct traffic. When certain workers go missing or act strangely, traffic jams form. Signals get lost. Systems break down.
In this case, the study found nine proteins that appear to be off-kilter in people with anxiety and other tough symptoms. Four — NMT1, DCAKD, DNPH1, and HIBADH — were strongly linked to anxiety. Five others — including ABL1 and SAP18 — showed up across multiple symptoms, like agitation, depression, and delusions.
These proteins aren’t random. They play roles in three critical systems:
- How brain cells talk to each other (synaptic signaling)
- How proteins fold and function properly
- The brain’s immune response
When any of these go wrong, it could spark the emotional chaos seen in dementia.
The team didn’t just look at single proteins. They also studied how groups of proteins work together — like teams in a factory. They found eight networks that were out of sync in people with more severe symptoms. This suggests it’s not just one broken part, but entire systems falling out of rhythm.
This doesn’t mean this treatment is available yet.
Still, experts say this is a major step. “We’ve been treating these symptoms blind for too long,” said one researcher not involved in the study. “Now we have a map. We can start building drugs that target the actual biology.”
So what does this mean for families today?
Right now, no new drugs are on the shelf. These findings won’t change treatment next week. But they do something powerful: they validate what families have known all along. These symptoms aren’t “just part of dementia.” They have a physical cause. And if we can find the cause, we can fix it.
The study has limits. It looked only at one brain region. The donors were mostly older, white, and from research registries — so results may not reflect everyone. And since it’s based on brain tissue after death, it can’t prove cause and effect.
But the patterns were strong and repeated across three separate groups of people. That makes the findings more trustworthy.
What happens next?
Drug developers can now use these proteins as targets. Think of them like bullseyes. Scientists can screen existing medicines or design new ones to hit these spots. Some of the proteins are already linked to other diseases, so drugs might be repurposed faster.
Clinical trials could begin in the next few years. But it will still take time. The brain is complex. Fixing one system might affect another. Safety comes first.
Still, for families worn down by sleepless nights and sudden outbursts, this research offers something rare: clarity.
The path to better treatments has finally begun.
7. ENDING
Researchers are now working to confirm these protein targets in living patients and test potential drugs in lab models, with human trials likely several years away but now grounded in solid biological evidence.
